CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
sorafenib tosylate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01817751
NCT01817751Phase 2Completed
CompareCT.gov

Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma

Virginia Commonwealth University·interventional·Posted Mar 25, 2013·Updated Jul 17, 2024

In Brief

A Phase 2 clinical trial evaluating sorafenib tosylate, valproic acid, and 1 other intervention for Glioblastoma and 3 related conditions. Completed, enrolled 47 participants across 1 site.

Detailed Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 25, 2013
Enrollment StartApr 11, 2013
Primary CompletionAug 27, 2020
Study CompletionMay 12, 2023
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 13.3 years ago

Interventions

sorafenib tosylatedrug

Given by mouth

valproic aciddrug

Given by mouth

sildenafil citratedrug

Given by mouth